查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018464

胃內球囊市場：按類型、最終用戶、分銷管道和應用分類－2026-2032年全球市場預測

Intragastric Balloon Market by Type, End User, Distribution Channel, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，胃內球囊市場價值將達到 2,349 萬美元，到 2026 年將成長至 2,924 萬美元，到 2032 年將達到 4,175 萬美元，複合年成長率為 8.56%。

主要市場統計數據
基準年 2025 2349萬美元
預計年份：2026年 2924萬美元
預測年份 2032 4175萬美元
複合年成長率 (%) 8.56%

對胃內球囊的發展歷程進行策略性概述，重點在於相關人員在臨床整合、提高安全性和推廣應用方面的優先事項。

胃內球囊市場已從體重管理的利基選擇發展成為多學科肥胖治療方案中的主流輔助性治療。器械材料、留置技術和臨床方案的進步提高了手術安全性，擴大了臨床接受度，促使醫院和專科診所重新評估治療流程。隨著相關人員尋求可擴展的解決方案來應對日益嚴重的肥胖及其代謝併發症，胃內球囊在保守藥物治療和減肥手術之間扮演著獨特的角色，提供了一種可逆、微創的選擇，可以整合到綜合治療方案中。

技術進步、整合式照護路徑和醫療保健提供者服務模式如何重塑臨床應用和商業性差異化。

胃內球囊領域正經歷著一場變革，這主要得益於技術進步、多學科診療模式的普及以及對個人化治療日益成長的重視。設備研發人員不斷改進填充介質、固定機制和取出技術。這些改進，加上更完善的患者篩選方案，降低了併發症發生率，並擴大了球囊治療的適用人群。同時，行為諮商、數位化監測和輔助藥物治療的整合，正使治療效果朝著更持久的體重管理方向發展，促使臨床醫生不再將球囊治療視為一種獨立的治療方法，而是將其視為綜合治療策略中不可或缺的一部分。

評估 2025 年美國關稅將如何影響整個胃內球囊生態系統的供應鏈策略、價格透明度和採購慣例。

2025年美國關稅調整的累積影響促使醫療設備製造商、經銷商和醫療採購團隊重新評估進口胃內球囊及相關耗材的供應鏈韌性和成本分配。關稅調整增加了某些類別零件和成品的接收成本，導致製造商將部分成本增加轉嫁給下游環節，同時探索替代採購管道和本地生產方案以確保利潤率。為此，醫院和診所的採購團隊正在採取重新談判合約、簽訂長期供應協議以及優先選擇生產地點多元化的供應商等措施。

將醫療設備類型、最終用戶環境、通路和臨床應用與商業化和臨床部署要求連結起來的詳細細分分析。

了解市場區隔趨勢對於產品開發和商業性部署至關重要。按類型分類，市場可分為內視鏡設備和非內視鏡設備，其中內視鏡設備又可細分為氣體式和液體式。這種區分會影響設備設計、操作流程和術後管理，並指南選擇哪些臨床團隊參與培訓和追蹤。此外，依最終用戶分類，市場可分為肥胖治療中心、診所和醫院，其中診所又可細分為門診診所和專科診所。這些機構在基礎設施、麻醉能力和診療路徑方面的差異決定了最佳的設備配置和服務方案。再者，按分銷管道分類，市場可分為醫院藥房和零售藥房，分銷策略必須考慮庫存管理、臨床醫生採購流程以及支援培訓和現場物流的專業分銷商的作用。最後，根據應用領域，市場細分為術前最佳化和減重，這種臨床細分會影響轉診模式、與保險公司的互動以及患者支援服務的協調。

美洲、歐洲、中東和非洲以及亞太市場的區域採用促進因素、監管差異和分銷挑戰。

區域趨勢顯著影響胃內球囊的臨床應用模式、監管管道和分銷策略。在美洲，隨著保險公司和醫療服務提供者日益重視非手術干預，成熟的肥胖中心和越來越多的門診診所開始採用胃內球囊作為治療選擇。該地區傾向選擇在不同患者族群中均能展現可重複療效，且能與現有多學科肥胖症治療方案結合的解決方案。同時，歐洲、中東和非洲地區的情況則截然不同，監管環境、報銷結構和臨床實務模式差異巨大。在一些市場，集中化的醫院系統和國家指南正在加速胃內球囊的推廣應用；而在另一些市場，保險公司覆蓋範圍和臨床醫生經驗的差異則需要開展針對性的教育和收集本地證據。亞太地區正經歷著胃內球囊的快速普及，這主要得益於肥胖症和代謝性疾病盛行率的上升、醫療服務模式的多樣化以及對微創替代療法的日益重視。在亞太地區的某些市場，專科診所數量不斷增加，患者數量龐大，消費者對侵入性較小的治療方案的興趣日益濃厚，這促使製造商開發本地化的培訓和患者支持計劃。

夥伴關係的策略著重於設備創新、臨床服務打包和合作模式，以推動產品普及和業務規模化。

領先的胃內球囊主要企業正著力應對幾項策略挑戰：臨床差異化、服務導向商業化和業務規模化。領先的器械開發商不斷投資改進器械設計，以減少不利事件並簡化植入和取出流程。他們也正在拓展產品組合，納入充氣式和充液式內視鏡球囊，以滿足不同臨床醫師的偏好和病患的生理特徵。除了器材本身，各公司也越來越多提供訓練、病人參與平台和後續服務等配套服務，以改善治療效果並減輕醫護人員的負擔。

切實可行的商業性、臨床和價值鏈策略，幫助領導者建立穩健的實施路徑，並使相關人員在價值交付方面達成一致。

產業領導者應優先考慮整合臨床證據、服務提供和供應鏈韌性的綜合方法，以加速胃內球囊解決方案的永續應用。首先，他們應投資以產生可靠的真實世界證據和病患報告結局（PRO），以支持術前最佳化和獨立減重適應症的臨床論證，從而促進與保險公司的溝通和臨床醫生的認可。其次，他們應建立全面的培訓和認證流程，以滿足肥胖治療中心、門診診所和專科診所的需求，以減少手術流程的差異並提高安全性。第三，他們應實現採購和物流策略的多元化，以減輕關稅波動的影響並縮短前置作業時間。這應包括在商業性可行的情況下建立本地製造夥伴關係。

採用綜合混合方法研究途徑，結合臨床訪談、監管審查和供應鏈分析，以檢驗實務見解。

本報告的研究採用混合方法，以確保研究結果既反映臨床實際情況，也反映商業性趨勢。主要資訊來源包括對肥胖治療中心、門診專科診所和醫院計畫的臨床醫生進行的結構化訪談，以及與醫院和零售藥局通路的採購經理和分銷合作夥伴的諮詢。次要資訊來源包括監管文件、臨床試驗註冊資訊以及專注於醫療設備安全性、有效性和病患報告結局的同行評審文獻。對這些資料來源進行交叉檢驗，使我們能夠識別出有關醫療設備效能、治療流程和推廣應用障礙的一致主題。

總結了決定在不同醫療保健環境中實施成功或失敗的臨床、商業性和營運因素。

總之，胃內球囊已發展成為現代肥胖治療中具有重要策略意義的工具，介於保守藥物治療和手術治療之間。器械創新、臨床方案改善和整合式照護模式的共同作用，提高了安全性並擴大了適用範圍，為肥胖治療中心、門診診所和整個醫院系統提供了切實可行的應用機會。然而，商業性成功並非僅取決於器械的性能。可驗證的療效、清晰的報銷途徑、穩健的供應鏈以及支持臨床醫生培訓和患者參與的可擴展服務模式都至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：胃內球囊市場：依類型分類

  • 內視鏡型
    • 氣體
    • 液體
  • 非內視鏡

第9章：胃內球囊市場：依最終用戶分類

  • 肥胖治療中心
  • 診所
    • 門診部
    • 專科診所
  • 醫院

第10章：胃內球囊市場：依通路分類

  • 醫院藥房
  • 零售藥房

第11章：胃內球囊市場：依應用領域分類

  • 術前最佳化
  • 減重

第12章：胃內球囊市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：胃內球囊市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：胃內球囊市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國胃內球囊市場

第16章：中國胃內球囊市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Allurion Technologies Inc.
  • Apollo Endosurgery Inc.
  • Baronova Inc.
  • Boston Scientific Corporation
  • Cook Medical LLC
  • Districlass Medical SA
  • Endalis SAS
  • Helioscopie Medical Implants
  • Johnson & Johnson
  • Medicone GmbH
  • Medtronic plc
  • Olympus Corporation
  • ReShape Lifesciences Inc.
  • Silimed Industria de Implantes Ltd
  • Spatz FGIA Inc.
Product Code: MRR-7C5681F8681E

The Intragastric Balloon Market was valued at USD 23.49 million in 2025 and is projected to grow to USD 29.24 million in 2026, with a CAGR of 8.56%, reaching USD 41.75 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 23.49 million
Estimated Year [2026] USD 29.24 million
Forecast Year [2032] USD 41.75 million
CAGR (%) 8.56%

Strategic introduction to intragastric balloon evolution highlighting clinical integration, safety improvements, and stakeholder priorities for adoption

The intragastric balloon segment has evolved from a niche alternative for weight management into a mainstream adjunct within multidisciplinary obesity care pathways. Advances in device materials, delivery techniques, and clinical protocols have increased procedural safety and broadened clinical acceptance, prompting hospitals and specialty clinics to re-evaluate treatment algorithms. As stakeholders seek scalable solutions to address rising rates of obesity and metabolic comorbidities, intragastric balloons occupy a distinct role between conservative medical therapy and bariatric surgery, offering a reversible, minimally invasive option that can be integrated into comprehensive care plans.

Clinical outcomes and patient experience remain central to adoption. Recent procedural optimizations and post-placement follow-up protocols have reduced adverse event profiles while improving sustained weight reduction when combined with behavioral and pharmacologic support. Payers and health systems are increasingly focused on patient selection criteria, real-world durability of outcomes, and cost-effectiveness relative to other interventions. Consequently, commercial strategies now emphasize robust clinical evidence, streamlined supply logistics, and partnerships with bariatric centers, outpatient specialty clinics, and hospital systems to embed intragastric balloons into longitudinal obesity care pathways.

Given this environment, manufacturers and health system leaders must balance device innovation with pragmatic considerations around training, reimbursement pathways, and center readiness. The interplay of regulatory evolution, clinician education, and patient demand will continue to shape positioning and uptake across diverse care settings.

How technological refinements, integrated care pathways, and provider delivery models are reshaping clinical adoption and commercial differentiation

The intragastric balloon landscape is undergoing transformative shifts driven by technological refinement, multidisciplinary care models, and heightened focus on personalized therapy. Device innovators have introduced modifications in fill media, anchoring mechanisms, and retrieval techniques, which, together with improved patient selection protocols, have reduced complication rates and expanded candidate eligibility. Concurrently, the integration of behavioral counseling, digital monitoring, and adjunctive pharmacotherapy has shifted outcomes toward more durable weight management, prompting clinicians to view balloons as one component of a comprehensive treatment strategy rather than a stand-alone cure.

Market-facing dynamics are also changing. Providers are reconfiguring service lines to offer outpatient and specialty clinic-based procedures, minimizing hospital resource utilization and enhancing patient convenience. At the same time, manufacturers are differentiating through bundled value propositions that include clinician training, follow-up programs, and patient engagement tools. Regulatory scrutiny remains rigorous, but clearer guidance has helped streamline adoption in regions where reimbursement frameworks are adapting to recognize long-term health economic benefits of obesity interventions.

As a result, competition is increasingly centered on post-procedural outcomes, care pathway integration, and commercial models that reduce friction for providers and patients. These shifts favor stakeholders who can demonstrate clinical efficacy within coordinated care programs and who can support scalable, low-complexity delivery models across a range of clinical settings.

Assessment of how 2025 United States tariffs have altered supply chain strategies, pricing transparency, and procurement practices across the intragastric balloon ecosystem

The cumulative impact of tariff changes in the United States during 2025 has prompted device manufacturers, distributors, and provider procurement teams to reassess supply chain resilience and cost allocation for imported intragastric balloons and related consumables. Tariff adjustments have led to higher landed costs for certain categories of components and finished devices, prompting manufacturers to pass some cost increases downstream while simultaneously exploring alternative sourcing and localized manufacturing to protect margins. Procurement teams within hospitals and clinics have responded by renegotiating contracts, seeking longer-term supply agreements, and prioritizing suppliers with diversified production footprints.

Beyond unit costs, tariffs have amplified the strategic importance of inventory planning and lead-time visibility. Providers have increased engagement with distributors to secure predictable deliveries and to minimize exposure to sudden tariff-driven price swings. Some manufacturers have accelerated investments in regional manufacturing capabilities and third-party partnerships to mitigate tariff risk and improve responsiveness to clinical demand. Regulatory compliance, customs clearance complexity, and documentation requirements have also consumed additional administrative resources, prompting supply chain teams to invest in customs expertise and digital tracking tools.

In this context, commercial strategies that emphasize transparency around total landed costs, warranty coverage, and service-level commitments have gained traction. Stakeholders that proactively adapt contracting practices, hedge supply routes, and communicate clear cost implications to purchasers will be better positioned to sustain adoption momentum despite tariff-induced headwinds.

In-depth segmentation analysis linking device type, end-user setting, distribution route, and clinical application to commercialization and clinical adoption imperatives

Understanding segmentation dynamics is essential to shaping product development and commercial outreach. Based on Type, market is studied across Endoscopic and Non Endoscopic, with Endoscopic further studied across Gas and Liquid; this distinction influences device design, procedural technique, and post-placement management, and it guides which clinical teams are engaged for training and follow-up. Separately, based on End User, market is studied across Bariatric Centers, Clinics, and Hospitals, with Clinics further studied across Outpatient Clinics and Specialty Clinics; differences in infrastructure, anesthesia capability, and care pathways across these settings determine preferred device profiles and service bundles. Furthermore, based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies, and distribution strategy must consider inventory management, clinician procurement processes, and the role of specialty distributors in supporting training and on-site logistics. Finally, based on Application, market is studied across Preoperative Optimization and Weight Loss, and this clinical segmentation affects referral patterns, payer interactions, and the alignment of patient support services.

Taken together, these segmentation axes reveal where clinical demand concentrates and where commercialization efforts should be tailored. For example, gas-filled versus liquid-filled endoscopic options appeal to different patient groups and procedural workflows, while clinics and outpatient specialty settings may prioritize devices that minimize procedure time and recovery needs. Distribution partnerships with hospital pharmacies will differ markedly from retail pharmacy models in terms of supply chain transparency and clinician interactions. Application-based segmentation underscores the need for outcome data specific to preoperative optimization versus primary weight reduction, which in turn shapes messaging to surgeons, primary care physicians, and multidisciplinary care teams.

In practical terms, manufacturers should align device features, training programs, and commercial terms with the dominant segmentation profiles in their target geographies, ensuring that product variants and service offerings match the operational realities of the end users and distribution partners they intend to serve.

Regional adoption drivers, regulatory variability, and distribution imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics significantly influence clinical adoption patterns, regulatory pathways, and distribution strategies for intragastric balloons. In the Americas, established bariatric centers and a growing number of outpatient clinics are integrating intragastric balloons into therapy mixes as payers and providers place greater emphasis on non-surgical interventions. This region favors solutions that demonstrate reproducible outcomes in diverse patient populations and that can integrate with existing multidisciplinary obesity programs. Meanwhile, Europe, Middle East & Africa present a heterogeneous landscape where regulatory frameworks, reimbursement environments, and clinical practice patterns vary widely; in some markets, centralized hospital systems and national guidelines accelerate adoption, whereas in others, variability in payer coverage and clinician experience necessitate targeted education initiatives and local evidence generation. Asia-Pacific exhibits rapid uptake driven by rising prevalence of obesity and metabolic disease, diverse care delivery models, and an emphasis on minimally invasive alternatives. In several Asia-Pacific markets, high-volume specialty clinics and consumer interest in less invasive options have encouraged manufacturers to develop localized training and patient support programs.

Across regions, supply chain considerations, regulatory timelines, and the maturity of reimbursement pathways shape go-to-market approaches. For example, regions with strong outpatient clinic networks may prioritize devices optimized for day-case procedures and limited anesthesia resources. Conversely, where hospital-centric care dominates, integrated service offerings that include clinician training, post-procedural monitoring, and durable follow-up will be more impactful. Effective regional strategies blend global clinical evidence with locally relevant real-world data and stakeholder engagement to build durable acceptance among clinicians, payers, and patients.

Competitive company strategies emphasizing device innovation, bundled clinical services, and partnership models to drive adoption and operational scale

Key companies operating in the intragastric balloon arena have converged around several strategic imperatives: clinical differentiation, service-oriented commercialization, and operational scalability. Leading device developers invest in iterative device design improvements to reduce adverse events and to simplify placement and removal workflows. Firms are also expanding portfolio breadth to include both gas-filled and liquid-filled endoscopic options, enabling them to address diverse clinician preferences and patient physiologies. Beyond devices, companies increasingly bundle training, patient engagement platforms, and follow-up services to improve outcomes and to reduce the burden on provider staff.

Strategic partnerships have become a common pathway to accelerate adoption; alliances with bariatric centers, specialty clinics, and distribution partners allow companies to demonstrate real-world effectiveness while building referral networks. Some players have pursued regional manufacturing relationships to enhance supply resilience and to optimize landed cost structures. In parallel, competitive differentiation is being sought through evidence generation-prospective registries, multi-center studies, and health economic analyses-to support payer engagement and to inform clinical guidelines. Companies that successfully balance product innovation with scalable service delivery and robust clinical evidence are positioning themselves to win favor among large health systems, outpatient providers, and specialist clinics seeking predictable outcomes and streamlined operations.

Actionable commercial, clinical, and supply chain measures for leaders to build resilient adoption pathways and align stakeholders around value delivery

Industry leaders should prioritize an integrated approach that aligns clinical evidence, service delivery, and supply chain resilience to accelerate sustainable adoption of intragastric balloon solutions. First, invest in robust real-world evidence generation and patient-reported outcomes to substantiate clinical claims across both preoperative optimization and standalone weight loss applications, thereby easing payer discussions and clinician acceptance. Second, create comprehensive training and credentialing pathways tailored to the needs of bariatric centers, outpatient clinics, and specialty clinics to reduce procedural variability and enhance safety profiles. Third, diversify sourcing and logistics strategies to mitigate exposure to tariff volatility and to shorten lead times, including localized manufacturing partnerships where commercially feasible.

Additionally, adapt commercial models to support different purchasing behaviors across hospital pharmacies and retail pharmacy channels by providing transparent total-cost-of-care communications and flexible contracting terms. Leverage digital patient engagement tools and multidisciplinary support programs to improve adherence to lifestyle interventions and to extend follow-up capabilities without overburdening clinical staff. Finally, pursue strategic collaborations with payer stakeholders to establish value-based arrangements or coverage pathways that reflect the long-term clinical and economic benefits of integrated obesity care. Collectively, these actions will strengthen the value proposition for intragastric balloons and support durable, scalable adoption across care settings.

Comprehensive mixed-methods research approach combining clinical interviews, regulatory review, and supply chain analysis to validate actionable insights

The research underpinning this report employed a mixed-methods approach to ensure that insights reflect both clinical realities and commercial dynamics. Primary inputs included structured interviews with clinicians across bariatric centers, outpatient specialty clinics, and hospital-based programs, as well as discussions with procurement leads and distribution partners active in hospital pharmacy and retail pharmacy channels. Secondary inputs comprised regulatory publications, clinical trial registries, and peer-reviewed literature focusing on device safety, efficacy, and patient-reported outcomes. Triangulation of these data sources enabled identification of consistent themes around device performance, procedural workflows, and barriers to adoption.

Analytical methods included comparative assessment of device design attributes-such as fill media and delivery systems-against procedural outcomes and care setting requirements. Supply chain and commercial impact analysis incorporated scenario testing to evaluate responses to tariff changes and sourcing disruptions, with attention to procurement behavior across different end-user environments. Throughout, findings were validated with clinician advisory panels and supply chain experts to ensure practical relevance and to surface actionable implications for manufacturers, providers, and payer stakeholders. The methodology emphasizes transparency in data sources and analytical assumptions while prioritizing clinical applicability and strategic utility for decision-makers.

Concluding synthesis highlighting the clinical, commercial, and operational levers that will determine successful adoption across diverse care settings

In summary, intragastric balloons have matured into a strategically important tool within contemporary obesity care, positioned between conservative medical management and surgical options. Device innovations, improved clinical protocols, and integrated care models have collectively enhanced safety and broadened applicability, creating meaningful opportunities for adoption across bariatric centers, outpatient clinics, and hospital systems. Nevertheless, commercial success depends on more than device performance; it requires demonstrable outcomes, clear reimbursement pathways, resilient supply chains, and scalable service models that support clinician training and patient engagement.

Tariff fluctuations and regional regulatory variability introduce complexity, but they also present opportunities for manufacturers to differentiate through transparent pricing, localized partnerships, and evidence-based commercial strategies. By aligning product development with end-user needs-taking into account the distinctions between endoscopic gas versus liquid options, varied clinic infrastructures, and distribution channel requirements-stakeholders can create compelling value propositions that resonate with providers and payers. The path forward favors those who couple clinical rigor with pragmatic commercialization to deliver reproducible outcomes and efficient care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intragastric Balloon Market, by Type

  • 8.1. Endoscopic
    • 8.1.1. Gas
    • 8.1.2. Liquid
  • 8.2. Non Endoscopic

9. Intragastric Balloon Market, by End User

  • 9.1. Bariatric Centers
  • 9.2. Clinics
    • 9.2.1. Outpatient Clinics
    • 9.2.2. Specialty Clinics
  • 9.3. Hospitals

10. Intragastric Balloon Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Retail Pharmacies

11. Intragastric Balloon Market, by Application

  • 11.1. Preoperative Optimization
  • 11.2. Weight Loss

12. Intragastric Balloon Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Intragastric Balloon Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Intragastric Balloon Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Intragastric Balloon Market

16. China Intragastric Balloon Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Allurion Technologies Inc.
  • 17.6. Apollo Endosurgery Inc.
  • 17.7. Baronova Inc.
  • 17.8. Boston Scientific Corporation
  • 17.9. Cook Medical LLC
  • 17.10. Districlass Medical S.A.
  • 17.11. Endalis S.A.S.
  • 17.12. Helioscopie Medical Implants
  • 17.13. Johnson & Johnson
  • 17.14. Medicone GmbH
  • 17.15. Medtronic plc
  • 17.16. Olympus Corporation
  • 17.17. ReShape Lifesciences Inc.
  • 17.18. Silimed Industria de Implantes Ltd
  • 17.19. Spatz FGIA Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRAGASTRIC BALLOON MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INTRAGASTRIC BALLOON MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INTRAGASTRIC BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INTRAGASTRIC BALLOON MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY GAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY GAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY GAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY NON ENDOSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY NON ENDOSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY NON ENDOSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY BARIATRIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY BARIATRIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY BARIATRIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY WEIGHT LOSS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY WEIGHT LOSS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY WEIGHT LOSS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS INTRAGASTRIC BALLOON MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. GCC INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GCC INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. GCC INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 115. GCC INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GCC INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 117. GCC INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. GCC INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. G7 INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. G7 INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 136. G7 INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. G7 INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 138. G7 INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. G7 INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. NATO INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. NATO INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NATO INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 143. NATO INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. NATO INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 145. NATO INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NATO INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL INTRAGASTRIC BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES INTRAGASTRIC BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA INTRAGASTRIC BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA INTRAGASTRIC BALLOON MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA INTRAGASTRIC BALLOON MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA INTRAGASTRIC BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA INTRAGASTRIC BALLOON MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA INTRAGASTRIC BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA INTRAGASTRIC BALLOON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)